AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
173.42
+0.93 (+0.54%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close172.49
Open173.83
Bid162.25 x 1200
Ask179.31 x 800
Day's Range172.20 - 174.42
52 Week Range142.81 - 256.80
Volume1,997,015
Avg. Volume2,743,734
Market Cap58.8B
Beta1.22
PE Ratio (TTM)N/A
EPS (TTM)-6.30
Earnings DateAug 1, 2018 - Aug 6, 2018
Forward Dividend & Yield2.88 (1.64%)
Ex-Dividend Date2018-05-17
1y Target Est208.43
Trade prices are not sourced from all markets
  • Allergan Promotes Male Botox Users With Big Campaign
    Bloomberg Video3 days ago

    Allergan Promotes Male Botox Users With Big Campaign

    Jun.21 -- Bloomberg's Drew Armstrong reports on the trend that's sweeping the medical aesthetics industry as the distributors of Botox, Dysport and Xeomin step up their efforts to sell cosmetic drugs to men. He speaks on "What'd You Miss?"

  • Boston Scientific, Masco, MasterCard, Allergan & Paypal
    CNBC Videos5 days ago

    Boston Scientific, Masco, MasterCard, Allergan & Paypal

    The "Halftime Report" traders give their top picks for the second half.

  • Developments for Allergan in June
    Market Realist3 days ago

    Developments for Allergan in June

    Allergan (AGN) is a specialty pharmaceutical company that develops various products through internal programs and in collaboration with other companies.

  • Allergan Promotes Male Botox Users With Big Campaign
    Bloomberg3 days ago

    Allergan Promotes Male Botox Users With Big Campaign

    Bloomberg's Drew Armstrong reports on the trend that's sweeping the medical aesthetics industry as the distributors of Botox, Dysport and Xeomin step up their efforts to sell cosmetic drugs to men. He ...

  • Allergan’s International Business Segment
    Market Realist4 days ago

    Allergan’s International Business Segment

    Allergan’s (AGN) International Business segment includes revenue from both its Specialized Therapeutics portfolio and its General Medicines portfolio from outside the US markets.

  • Allergan’s US General Medicines Segment
    Market Realist4 days ago

    Allergan’s US General Medicines Segment

    Allergan’s (AGN) US General Medicines segment includes women’s health products, central nervous system products, anti-infective products, gastrointestinal products, and diversified brands.

  • Allergan’s US Specialized Therapeutics Segment
    Market Realist4 days ago

    Allergan’s US Specialized Therapeutics Segment

    As discussed earlier, Allergan’s (AGN) US Specialized Therapeutics segment includes revenue from the US sales of specialized products, including eye care products, medical esthetics products, dermatology products, neuroscience products, and urology products.

  • Wanted: Wrinkled Men Not Afraid of Needles for ‘ Brotox’ Revival
    Bloomberg4 days ago

    Wanted: Wrinkled Men Not Afraid of Needles for ‘ Brotox’ Revival

    At Marina ManLand in the Los Angeles area, plastic surgeon Grant Stevens is injecting Botox into men as never before. “I’m doing more male surgery than ever before in my entire career,” Stevens said. ManLand is emblematic of a trend that’s sweeping the medical aesthetics industry as the distributors of drugs such as Botox, Dysport and Xeomin step up their efforts to sell cosmetic drugs to men.

  • Examining the Performances of Allergan’s Business Segments
    Market Realist5 days ago

    Examining the Performances of Allergan’s Business Segments

    As we discussed, Allergan (AGN) has restructured its business over the last few years, and now it reports its business revenue in three segments: US Specialized Therapeutics, US General Medicines, and International Business.

  • Allergan’s Quarterly Revenue Trend
    Market Realist5 days ago

    Allergan’s Quarterly Revenue Trend

    As discussed earlier, Allergan (AGN) reported a 2.8% rise in revenue to $3.7 billion during the first quarter of 2018 compared to revenue of $3.6 billion during the first quarter of 2017.

  • Analysts’ Estimates and Recommendations for Allergan in June
    Market Realist5 days ago

    Analysts’ Estimates and Recommendations for Allergan in June

    Wall Street analysts expect Allergan’s (AGN) adjusted EPS to be $4.10 on revenue of $3.9 billion during the second quarter, a 2.7% fall compared to $4.0 billion in the second quarter of 2017. No analysts have recommended “sells” on Allergan stock. Allergan’s stock price has fallen nearly 27.1% over the last 12 months but has risen ~5.0% in 2018 year-to-date.

  • A Look at Allergan’s Valuation as of June 19
    Market Realist5 days ago

    A Look at Allergan’s Valuation as of June 19

    Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.

  • Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play
    InvestorPlace10 days ago

    Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play

    The U.S. government is shifting its focus from accusing drug companies of overcharging to encouraging the marketplace to operate more competitively. On May 31, FDA Commissioner Scott Gottlieb, announced a draft guidance that will limit drug companies in delaying generics to market. Previously, generics needed to negotiate with branded firms.

  • Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
    Zacks10 days ago

    Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

    Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

  • TheStreet.com10 days ago

    Is Goldman Sachs Going to Be the Next Allergan?

    Don't count on it. The fundamentals paint two very different pictures, Cramer says.

  • Allergan (AGN) Presents Positive Data on Glaucoma Candidate
    Zacks11 days ago

    Allergan (AGN) Presents Positive Data on Glaucoma Candidate

    Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.

  • Allergan appoints former Abbott executive to its board
    Reuters11 days ago

    Allergan appoints former Abbott executive to its board

    Allergan, whose director Patrick O'Sullivan will retire from the board in July, said its board will continue to have 12 members of which 10 are independent, following the changes. Freyman, who retired from Abbott in 2017, most recently served as executive vice president, finance and administration for the company since June 2015.

  • GlobeNewswire11 days ago

    Detailed Research: Economic Perspectives on Stein Mart, Asbury Automotive Group, Sprint, The Kraft Heinz, Allergan plc, and Fitbit — What Drives Growth in Today's Competitive Landscape

    NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Stein ...

  • PR Newswire11 days ago

    Allergan Continues Active Board Refreshment Process

    DUBLIN, June 14, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced that Thomas C. Freyman will join its Board of Directors effective immediately, as part of the company's ongoing board refreshment process. Mr. Freyman, a former Executive Vice President of Finance and Administration at Abbott Laboratories, brings nearly 40 years of healthcare industry and finance experience to Allergan's Board.

  • PR Newswire12 days ago

    Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant for IOP Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension

    DUBLIN, June 13, 2018 /PRNewswire/ -- Allergan plc, (AGN), a leading global pharmaceutical company, today announced the release of new topline clinical trial data on Bimatoprost SR, the first-in-class sustained-release, biodegradable implant for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bimatoprost SR is designed to lower IOP for at least 4 months, achieving clinical goals while freeing patients from daily eye drop regimens. In this first Phase 3 clinical study of 594 subjects with open-angle glaucoma or ocular hypertension, Bimatoprost SR reduced IOP by approximately 30 percent over the 12-week primary efficacy period, meeting the predefined criteria for non-inferiority to the study comparator, timolol.

  • Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study
    Zacks13 days ago

    Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study

    Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.

  • Reuters14 days ago

    Allergan oral migraine drug succeeds in study

    Allergan Plc said on Monday its oral migraine drug met the main goal across all doses in a study, with a statistically significant reduction in monthly headache days in patients with episodic migraine. The treatment, atogepant, belongs to a class of migraine drugs also being developed by Eli Lilly and Alder Biopharmaceuticals that target a protein associated with pain signaling called calcitonin gene-related peptide (CGRP). Last month, the U.S. Food and Drug Administration approved Amgen Inc's CGRP treatment Aimovig, which is self injected monthly and will have a list price of $6,900 a year, or $575 a month.

  • What to Do After Axovant Sciences Ltd Skyrockets Three-fold in a Month
    InvestorPlace14 days ago

    What to Do After Axovant Sciences Ltd Skyrockets Three-fold in a Month

    As a micro-cap company, Axovant Sciences Ltd (NASDAQ:AXON) is naturally fraught with risks. The company is losing money and debt levels are elevated at 0.49 times equity. AXO-Lenti-PD is a gene therapy for treating Parkinson’s disease.

  • PR Newswire14 days ago

    Allergan's Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial

    - Study meets primary endpoint for all doses and dose regimens - - Atogepant was well tolerated and there was no signal of hepatotoxicity with daily administration over 12 weeks - - Allergan will continue ...

  • Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant
    Zacks17 days ago

    Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant

    Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.